Emergent Technologies, Inc. (ETI) announced today that its target discovery portfolio company, Pure MHC, and global biopharmaceutical company, AbbVie (NYSE:ABBV), will embark on a research and license agreement to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancers.